TC-2559
TC-2559 is an orally active, selective central nervous system Nicotinic acetylcholine receptor agonist with a Ki value of 5 nM. TC-2559 activates central nervous system receptors selectively over peripheral nervous system receptors. TC-2559 improves scopolamine (HY-N0296)-induced cognitive impairment and enhances radial arm maze performance. TC-2559 can be used in the research of neurodegenerative diseases.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 326924-19-0
- 分子式: C12H18N2O·1/2C6H10O8
- 分子量:311.30
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
TC-2559 binds with high affinity to nicotinic acetylcholine receptors in rat brain cortex membranes, with a Ki of 5.5 nM[1].
TC-2559 (0.01-100 μM) potently and efficaciously stimulates dopamine release from rat striatal synaptosomes (EC50 = 203 nM) and induces significantly less residual inhibition of dopamine release than nicotine following pre-incubation[1].
TC-2559 (0.01-90 μM) potently stimulates 86Rb+ efflux from rat thalamic synaptosomes, with an EC50 of 367 nM and efficacy comparable to nicotine[1].
TC-2559 (10 μM; 2 h) significantly protects cultured fetal rat brain cells from glutamate-induced neurotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
TC-2559 (1-10 μmol/kg; p.o.; single administration or daily administration for 6 consecutive days) enhances radial arm maze working memory performance in male Sprague-Dawley rats (acute administration), improves their reference memory at an acute dose of 1 μmol/kg, and repeated oral administration (1-6 μmol/kg) further enhances their working memory performance[1].
TC-2559 (1-10 μmol/kg; subcutaneous injection; single administration) induces dose-dependent hypoactivity in male Sprague-Dawley rats. A dose of 1 μmol/kg produces a persistent effect, and both 1 μmol/kg and 10 μmol/kg doses significantly reduce locomotor activity over 30 minutes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 200-350 g, scopolamine-induced amnesia)[1]
-
Dosage:0.6 μmol/kg; 1 μmol/kg; 3 μmol/kg; 6 μmol/kg; 10 μmol/kg
-
Administration:s.c.; single dose
-
Result:Significantly attenuated scopolamine-induced reduction in step-through retention latencies at 3 μmol/kg (median latency 88.7 s) and 6 μmol/kg (median latency 105.7 s).
Did not produce statistically significant attenuation at 0.6 μmol/kg, 1 μmol/kg, and 10 μmol/kg compared to scopolamine alone.
化学情報
-
CAS 番号 326924-19-0
-
分子量 311.30
-
分子式 C12H18N2O·1/2C6H10O8
-
SMILES
OC([C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O)=O.CNCC/C=C/C1=CN=CC(OCC)=C1.[1/2]
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
- TC-2559
- 326924-19-0
- TC2559
- TC 2559
- nAChR
- scopolamine-induced cognitive deficits
- TE671/RD cells
- CNS nicotinic acetylcholine receptor
- PNS receptors
- dopamine
- ganglion-type nicotinic acetylcholine receptors
- muscle-type nicotinic acetylcholine receptors
- glutamate-induced neurotoxicity
- PC12 cells
- radial arm maze
- Inhibitor
- inhibitor
- inhibit